



# Quarterly Investor Webinar

---

13<sup>TH</sup> MAY 2026

# Welcome

# Disclaimer



This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

# Company Update

David Atkins,  
CEO & Managing Director



# Company Update & Key Highlights



Executing the transition from development to commercialisation

## 1. Regulatory and market access milestones advancing

- Continued progress across regulatory pathways
- NHS evaluation program commenced

## 2. Commercial rollout progressing

- Commercial readiness activities completed
- Services Agreement secured with 4Cyte Pathology

## 3. Early clinical adoption of ColoSTAT® underway

- Initial commercial traction achieved
- Positive engagement from clinicians and healthcare providers

## 4. Stronger balance sheet supports execution

- RHYO options exercise underwritten for \$5.2 million

## 5. Focused on scaling commercial opportunity

- Advancing awareness, adoption and strategic growth initiatives

# Commercial Update

Jackson Jones,  
Chief Commercial Officer



# Commercial Update

Building market engagement and early adoption

## 1. Growing clinician engagement

- Increasing awareness of ColoSTAT®
- Positive feedback from healthcare providers

## 2. Early adoption underway

- Initial commercial experience established
- Building reference sites and user familiarity

## 3. Large market opportunity

- Significant unmet need in colorectal cancer screening
- Opportunity to improve participation and outcomes

## 4. Focused commercial execution

- Expanding market engagement
- Supporting adoption and education initiatives
- Scaling strategically

# Questions?



**Thank you!**

[investors@rhythmbio.com](mailto:investors@rhythmbio.com)

[www.rhythmbio.com](http://www.rhythmbio.com)

A copy of this webinar and presentation will be available at [rhythmbio.com](http://rhythmbio.com) this week.